CXCR1/CXCR2 antagonism is effective in pulmonary defense against Klebsiella pneumoniae infection

Biomed Res Int. 2013:2013:720975. doi: 10.1155/2013/720975. Epub 2013 Mar 18.

Abstract

Klebsiella pneumoniae-associated pathology is largely mediated by neutrophilic inflammation. In this study, we administered Klebsiella pneumoniae to experimental guinea pig groups and the ELR-CXC chemokine antagonist CXCL8(3-72), ceftazidime, and dexamethasone to different groups, respectively. After 24 h, we assessed the animal's pulmonary inflammatory levels, including gross histopathology, airway neutrophilia, lung myeloperoxidase levels, expressions of CXCL8 and TNF, and airway bacterial loads. Compared with ceftazidime and dexamethasone treatments, the administration of the ELR-CXC chemokine antagonist CXCL8(3-72) alone was more effective than other methods, although it did not markedly attenuate the bacterial load. These results suggest new methods for the treatment of Klebsiella pneumoniae pathology.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Ceftazidime / administration & dosage
  • Dexamethasone / administration & dosage
  • Guinea Pigs
  • Humans
  • Interleukin-8 / antagonists & inhibitors
  • Interleukin-8 / metabolism
  • Klebsiella Infections / drug therapy
  • Klebsiella Infections / microbiology
  • Klebsiella Infections / pathology
  • Klebsiella pneumoniae / drug effects*
  • Klebsiella pneumoniae / pathogenicity
  • Lung / metabolism*
  • Lung / microbiology
  • Lung / pathology
  • Pneumonia / metabolism
  • Pneumonia / pathology
  • Receptors, Interleukin-8A / antagonists & inhibitors*
  • Receptors, Interleukin-8B / antagonists & inhibitors*

Substances

  • Interleukin-8
  • Receptors, Interleukin-8A
  • Receptors, Interleukin-8B
  • Dexamethasone
  • Ceftazidime